GT307 / Grit Biotechnology - LARVOL DELTA

A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of Metastatic and Recurrent Advanced Solid Tumors (clinicaltrials.gov) - P=N/A | N=0 | Withdrawn | Sponsor: Grit Biotechnology | N=16 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of Metastatic and Recurrent Advanced Solid Tumors (clinicaltrials.gov) - P=N/A | N=16 | Not yet recruiting | Sponsor: Grit Biotechnology

New trial • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A CRISPR/Cas9 screening platform ImmuT Finder® enables in vivo T cell functional screening and identification of potent immunoregulatory targets for next-generation T cell therapy (AACR 2024) - "Furthermore, GT307 KO TCR-T and TIL demonstrated significantly improved tumor control in mouse models than their unedited counterparts and promoted long-term persistence with low support of IL-2. In summary, these data demonstrated that our ImmuT Finder® platform enables discovery of potent and/or novel targets for the development of T cell product and supports the clinical assessment of GT307 as a next-generation T cell therapy."

Preclinical • Oncology • Solid Tumor • IL2

uBriGene Biosciences (uBriGene), a global CDMO leader, is excited to announce that its strategic partner, Grit Biotechnologies, has received FDA clearance for its Investigational New Drug (IND) application on GT307, a next-generation gene-edited Tumor-Infiltrating Lymphocytes (TIL) therapy. (Newswire)

IND • Oncology

Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients with Advanced Colorectal Cancer (clinicaltrials.gov) - P=N/A | N=18 | Recruiting | Sponsor: Grit Biotechnology

New trial • Colorectal Cancer • Oncology • Solid Tumor

Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid Tumours (clinicaltrials.gov) - P=N/A | N=18 | Recruiting | Sponsor: Grit Biotechnology

New trial • Oncology • Solid Tumor

Autologous Tumor-Infiltrating Lymphocyte (GT307 Injection ) for Treatment of Patients With Solid Tumours (clinicaltrials.gov) - P=N/A | N=18 | Recruiting | Sponsor: Grit Biotechnology

New trial • Oncology • Solid Tumor